SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ASLAN Pharmaceuticals Limited (ASLN) .
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
SharesGrow 综合评分： 37/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ASLN
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.03
EV/EBITDA0.0
每股数据
EPS (TTM)$-67.25
每股账面价值$0.00
每股营收$18.24
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2014 |
$-720.25 |
$0.00 |
$-7.36M |
- |
| 2015 |
$-151.25 |
$0.00 |
$-13.33M |
- |
| 2016 |
$-43.25 |
$11.49M |
$-9M |
-78.4% |
| 2017 |
$-195.50 |
$0.00 |
$-40.71M |
- |
| 2018 |
$-176.00 |
$0.00 |
$-42.19M |
- |
| 2019 |
$-181.25 |
$3M |
$-47.07M |
-1568.9% |
| 2020 |
$-58.25 |
$0.00 |
$-17.91M |
- |
| 2021 |
$-66.50 |
$0.00 |
$-34.71M |
- |
| 2022 |
$-92.00 |
$0.00 |
$-51.38M |
- |
| 2023 |
$-67.25 |
$12M |
$-44.22M |
-368.5% |
